Lantheus Holdings, Inc. (LNTH)

業務介紹

藍圖控股公司開發、製造和商業化診斷和治療產品,協助臨床醫生診斷和治療全球心臟、癌症和其他疾病。它提供以下產品:

DEFINITY - 用於心臟超聲波檢查的微泡超聲增強劑
TechneLite - 用於核醫學的鎝發生器
Xenon-133 - 評估肺功能
Neurolite - 識別由於中風而阻塞或減少血流的大腦區域
Cardiolite - 可注射的Tc-99m標記成像劑
Thallium-201 - 檢測心血管疾病
Gallium-67 - 檢測各種感染和惡性腫瘤

該公司還提供以下產品:

AZEDRA - 治療成人和兒童患者的放射性治療藥物
Automated Bone Scan Index - 量化前列腺癌骨掃描熱點以計算疾病負擔
Cobalt (Co 57) - 非藥品放射化學品
RELISTOR - 治療阿片誘發性便秘
PYLARIFY - 用於淋巴結、骨骼和軟組織轉移的可視化,以確定前列腺癌復發和/或轉移的存在或缺失

該公司還在開發以下產品:

flurpiridaz F 18 - 評估心臟血流
1095 - 一種PSMA靶向碘-131標記的小分子
LMI 1195 - 用於兒童和成人神經母細胞瘤
PYLARIFY AI - 一種基於人工智能的醫療設備軟件,用於對前列腺癌PSMA PET/CT圖像進行標準化定量評估
leronlimab - 一種實驗性人源化單克隆抗體

該公司為放射藥房、分銷商、綜合服務網絡、醫院、診所和集團實踐提供服務。它與多家公司建立了戰略合作夥伴關係。該公司成立於1956年,總部位於馬薩諸塞州北比勒里卡。



Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

公司網址

https://www.lantheus.com